Your browser doesn't support javascript.
A Prospective Cohort Study in Nonhospitalized Household Contacts With Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Symptom Profiles and Symptom Change Over Time.
Yousaf, Anna R; Duca, Lindsey M; Chu, Victoria; Reses, Hannah E; Fajans, Mark; Rabold, Elizabeth M; Laws, Rebecca L; Gharpure, Radhika; Matanock, Almea; Wadhwa, Ashutosh; Pomeroy, Mary; Njuguna, Henry; Fox, Garrett; Binder, Alison M; Christiansen, Ann; Freeman, Brandi; Gregory, Christopher; Tran, Cuc H; Owusu, Daniel; Ye, Dongni; Dietrich, Elizabeth; Pevzner, Eric; Conners, Erin E; Pray, Ian; Rispens, Jared; Vuong, Jeni; Christensen, Kim; Banks, Michelle; O'Hegarty, Michelle; Mills, Lisa; Lester, Sandra; Thornburg, Natalie J; Lewis, Nathaniel; Dawson, Patrick; Marcenac, Perrine; Salvatore, Phillip; Chancey, Rebecca J; Fields, Victoria; Buono, Sean; Yin, Sherry; Gerber, Susan; Kiphibane, Tair; Dasu, Trivikram; Bhattacharyya, Sanjib; Westergaard, Ryan; Dunn, Angela; Hall, Aron J; Fry, Alicia M; Tate, Jacqueline E; Kirking, Hannah L.
  • Yousaf AR; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Duca LM; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Chu V; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Reses HE; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Fajans M; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Rabold EM; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Laws RL; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Gharpure R; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Matanock A; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Wadhwa A; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Pomeroy M; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Njuguna H; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Fox G; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Binder AM; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Christiansen A; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Freeman B; Laboratory Leadership Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Gregory C; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Tran CH; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Owusu D; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Ye D; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Dietrich E; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Pevzner E; North Shore Health Department, Milwaukee, Wisconsin, USA.
  • Conners EE; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Pray I; Laboratory Leadership Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Rispens J; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Vuong J; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Christensen K; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Banks M; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • O'Hegarty M; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Mills L; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Lester S; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Thornburg NJ; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Lewis N; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Dawson P; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Marcenac P; Wisconsin Department of Health, Milwaukee, Wisconsin, USA.
  • Salvatore P; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Chancey RJ; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Fields V; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Buono S; Utah Department of Health, Salt Lake City, Utah, USA.
  • Yin S; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Gerber S; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Kiphibane T; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Dasu T; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Bhattacharyya S; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Westergaard R; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Dunn A; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Hall AJ; Utah Department of Health, Salt Lake City, Utah, USA.
  • Fry AM; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Tate JE; Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
  • Kirking HL; COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Clin Infect Dis ; 73(7): e1841-e1849, 2021 10 05.
Article in English | MEDLINE | ID: covidwho-1455251
Semantic information from SemMedBD (by NLM)
1. Asymptomatic Infections AFFECTS viral transmission
Subject
Asymptomatic Infections
Predicate
AFFECTS
Object
viral transmission
2. Symptoms PROCESS_OF Persons
Subject
Symptoms
Predicate
PROCESS_OF
Object
Persons
3. Infectious disease prevention / control TREATS Community
Subject
Infectious disease prevention / control
Predicate
TREATS
Object
Community
4. Asymptomatic Infections AFFECTS viral transmission
Subject
Asymptomatic Infections
Predicate
AFFECTS
Object
viral transmission
5. Symptoms PROCESS_OF Persons
Subject
Symptoms
Predicate
PROCESS_OF
Object
Persons
6. Infectious disease prevention / control TREATS Community
Subject
Infectious disease prevention / control
Predicate
TREATS
Object
Community
ABSTRACT

BACKGROUND:

Improved understanding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spectrum of disease is essential for clinical and public health interventions. There are limited data on mild or asymptomatic infections, but recognition of these individuals is key as they contribute to viral transmission. We describe the symptom profiles from individuals with mild or asymptomatic SARS-CoV-2 infection.

METHODS:

From 22 March to 22 April 2020 in Wisconsin and Utah, we enrolled and prospectively observed 198 household contacts exposed to SARS-CoV-2. We collected and tested nasopharyngeal specimens by real-time reverse-transcription polymerase chain reaction (rRT-PCR) 2 or more times during a 14-day period. Contacts completed daily symptom diaries. We characterized symptom profiles on the date of first positive rRT-PCR test and described progression of symptoms over time.

RESULTS:

We identified 47 contacts, median age 24 (3-75) years, with detectable SARS-CoV-2 by rRT-PCR. The most commonly reported symptoms on the day of first positive rRT-PCR test were upper respiratory (n = 32 [68%]) and neurologic (n = 30 [64%]); fever was not commonly reported (n = 9 [19%]). Eight (17%) individuals were asymptomatic at the date of first positive rRT-PCR collection; 2 (4%) had preceding symptoms that resolved and 6 (13%) subsequently developed symptoms. Children less frequently reported lower respiratory symptoms (21%, 60%, and 69% for <18, 18-49, and ≥50 years of age, respectively; P = .03).

CONCLUSIONS:

Household contacts with laboratory-confirmed SARS-CoV-2 infection reported mild symptoms. When assessed at a single timepoint, several contacts appeared to have asymptomatic infection; however, over time all developed symptoms. These findings are important to inform infection control, contact tracing, and community mitigation strategies.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Etiology study / Observational study / Prognostic study Limits: Adult / Child / Humans / Young adult Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: Cid

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Etiology study / Observational study / Prognostic study Limits: Adult / Child / Humans / Young adult Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: Cid